Scarica l'app Stockscreener
138.19
4.19%
-6.05
Belite Bio Inc Adr Borsa (BLTE) Ultime notizie
BLTE Reiterated by HC Wainwright & Co. -- Price Target Maintained at $200 - GuruFocus
The Technical Signals Behind (BLTE) That Institutions Follow - Stock Traders Daily
Belite Bio Completes Rolling Submission of New Drug Application to U.S. Food and Drug Administration for Tinlarebant for the Treatment of Stargardt Disease Type 1 - markets.businessinsider.com
Belite Bio Completes Rolling Submission of New Drug Application to U.S. Food and Drug Administration for Tinlarebant for the Treatment of Stargardt Disease Type 1 - GlobeNewswire Inc.
Belite Bio (NASDAQ: BLTE) completes FDA NDA submission for tinlarebant in Stargardt disease - Stock Titan
BLTE Stock Price, Quote & Chart - ChartMill
Belite Bio Shares Surge on Drug Filing Hopes - TipRanks
Precision Trading with Belite Bio Inc (BLTE) Risk Zones - Stock Traders Daily
Belite Bio to Participate in the Goldman Sachs 47th Annual Global Healthcare Conference - markets.businessinsider.com
Why Belite Bio Stock Is Sinking Again Today - TipRanks
Belite Bio Stock Tumbles as Wall Street Cools - TipRanks
Full Transcript: Belite Bio Q1 2026 Earnings Call - Sahm
Belite Bio Stock Slumps On Mounting Doubts - TipRanks
Belite Bio (BLTE) Hovers Near Resistance as Price Action Remains MutedBear Flag - The Legal Advocate
Mizuho lowers Belite Bio stock price target to $215 on valuation - Investing.com UK
Mizuho lowers Belite Bio stock price target to $215 on valuation By Investing.com - Investing.com South Africa
Mizuho Adjusts Price Target on Belite Bio to $215 From $223, Maintains Outperform Rating - Moomoo
Technical Reactions to BLTE Trends in Macro Strategies - Stock Traders Daily
Belite Bio shares rise after first-quarter earnings outperform expectations (BLTE) - MSN
Benchmark reiterates Belite Bio stock rating on drug development progress By Investing.com - Investing.com Nigeria
Benchmark reiterates Belite Bio stock rating on drug development progress - Investing.com
Analysts Are Bullish on Top Healthcare Stocks: Belite Bio, Inc. ADR (BLTE), Centene (CNC) - The Globe and Mail
Belite Bio: Buy Rating Reiterated as Tinlarebant Advances Toward 1Q27 Stargardt NDA Approval with Unchanged $200 Price Target - TipRanks
H.C. Wainwright reiterates Belite Bio stock rating on NDA progress By Investing.com - Investing.com South Africa
Earnings Scheduled For May 20, 2026 - Sahm
H.C. Wainwright reiterates Belite Bio stock rating on NDA progress - Investing.com
Belite Bio Q1 2026 Earnings Call Transcript - MarketBeat
Belite Bio Inc (BLTE) Q1 2026 Earnings Call Highlights: Strategic Advancements Amid Rising Expenses By GuruFocus - Investing.com Canada
Belite Bio Ramps Toward Tinlarebant Launch - TipRanks
Belite Bio Q1 Earnings Call Highlights - Yahoo Finance
Belite Bio (BLTE) Q1 2026 Earnings Transcript - The Globe and Mail
Earnings call transcript: Belite Bio beats Q1 2026 EPS estimates, stock dips - Investing.com
Belite Bio Releases Q1 2026 Financial Results - AlphaStreet
Belite Bio Kicks Off Tinlarebant NDA and Ramps Up Commercial Build-Out on Strong Cash Base - TipRanks
Belite Bio Q1 Adjusted Loss Widens - marketscreener.com
Belite Bio stock gains 2% on first-quarter earnings beat By Investing.com - Investing.com India
Earnings Flash (BLTE) Belite Bio, Inc Posts Q1 Adjusted Loss $0.34 per Share, vs. FactSet Est of $-0.69 - marketscreener.com
Belite Bio stock gains 2% on first-quarter earnings beat - Investing.com
Belite Bio Reports Unaudited First Quarter 2026 Financial Results and Provides a Corporate Update - The Manila Times
Belite Bio (NASDAQ: BLTE) starts tinlarebant NDA as Q1 2026 loss deepens - Stock Titan
Belite Bio receives Swiss orphan drug status for tinlarebant By Investing.com - Investing.com Nigeria
Belite Bio receives Swiss orphan drug status for tinlarebant - Investing.com
1.27%
1.43%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):